The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.

开始日期2024-04-16

申办/合作机构

The University of Texas at Arlington

NCT06026813 / CompletedN/AIIT

Pressure Alternating Shoes (PAS) for Prevention of Diabetic Foot Ulcers

The project is designed to develop and test Pressure Alternating Shoes (PAS), which will periodically off-load certain regions of the foot in order to prevent foot ulcers. An automated dual layer insole compromised of an active pressurized actuator array in combination with a passive compliant layer on top of each actuator to modulate and distribute the plantar surface pressure as desired will be tested. This device will allow us to simultaneously load and offload select areas of the foot using the active layer by inflating and deflating individual actuators using pressurized air. After offloading, the remaining load will be distributed to other areas with inflated actuators. Automatic modulation will be provided through programmable control hardware which will cyclically relieve mechanical loading based on a prescribed duration and frequency.

开始日期2024-03-07

申办/合作机构

The University of Texas Southwestern Medical Center

[+2]

NCT06150989 / RecruitingN/AIIT

A Biobehavioral Approach to Understand the Multilevel Determinants of Cardiovascular Health in Black Women

This pilot study uses a state-of-the-science combination of remote behavioral monitoring, real-time experience sampling, in-lab physiological assessments, and extraction of neighborhood-level characteristics to (1) Examine the impact of daily experience (i.e., racial discrimination, affective states, stress) on health behaviors (i.e., physical activity, sedentary behavior, sleep) at the intrapersonal level among Black women; (2) Test the association between daily behaviors and impairments in biomarkers associated with vascular function/health (i.e., augmented systemic inflammation and oxidative stress, impaired peripheral/cerebral vascular function, increased large artery stiffness), as well as the impact of daily experience on the relationship between behaviors and vascular function; and (3) Explore the influence of neighborhood-level characteristics (i.e., social environment factors: i.e., neighborhood income and poverty, racial composition; and built environment context, such as park density and walkability) on daily experience and health behaviors.

开始日期2024-03-04

申办/合作机构

The University of Texas at Arlington

[+1]

100 项与 The University of Texas at Arlington 相关的临床结果

登录后查看更多信息

0 项与 The University of Texas at Arlington 相关的专利（医药）

登录后查看更多信息

33,590

项与 The University of Texas at Arlington 相关的文献（医药）

2025-01-01·MEDICAL IMAGE ANALYSIS

Learning lifespan brain anatomical correspondence via cortical developmental continuity transfer

Article

作者: Wu, Zhengwang ; Liu, Tianming ; Yu, Xiaowei ; Wu, Zihao ; Lyu, Yanjun ; Wang, Li ; Zhang, Lu ; Zhao, Lin ; Zhu, Dajiang ; Li, Gang ; Wang, Xianqiao ; Dai, Haixing

Identifying anatomical correspondences in the human brain throughout the lifespan is an essential prerequisite for studying brain development and aging. But given the tremendous individual variability in cortical folding patterns, the heterogeneity of different neurodevelopmental stages, and the scarce of neuroimaging data, it is difficult to infer reliable lifespan anatomical correspondence at finer scales. To solve this problem, in this work, we take the advantage of the developmental continuity of the cerebral cortex and propose a novel transfer learning strategy: the model is trained from scratch using the age group with the largest sample size, and then is transferred and adapted to the other groups following the cortical developmental trajectory. A novel loss function is designed to ensure that during the transfer process the common patterns will be extracted and preserved, while the group-specific new patterns will be captured. The proposed framework was evaluated using multiple datasets covering four lifespan age groups with 1,000+ brains (from 34 gestational weeks to young adult). Our experimental results show that: 1) the proposed transfer strategy can dramatically improve the model performance on populations (e.g., early neurodevelopment) with very limited number of training samples; and 2) with the transfer learning we are able to robustly infer the complicated many-to-many anatomical correspondences among different brains at different neurodevelopmental stages. (Code will be released soon: https://github.com/qidianzl/CDC-transfer).

2024-12-01·Applied microbiology and biotechnology

Antimicrobial resistance in aeromonads and new therapies targeting quorum sensing

Review

作者: Cheney, Gabrielle L ; Sha, Jian ; Rosenzweig, Jason A ; Chopra, Ashok K ; Neil, Blake

Abstract:

Aeromonas species (spp.) are well-known fish pathogens, several of which have been recognized as emerging human pathogens. The organism is capable of causing a wide spectrum of diseases in humans, ranging from gastroenteritis, wound infections, and septicemia to devastating necrotizing fasciitis. The systemic form of infection is often fatal, particularly in patients with underlying chronic diseases. Indeed, recent trends demonstrate rising numbers of hospital-acquired Aeromonas infections, especially in immuno-compromised individuals. Additionally, Aeromonas-associated antibiotic resistance is an increasing challenge in combating both fish and human infections. The acquisition of antibiotic resistance is related to Aeromonas’ innate transformative properties including its ability to share plasmids and integron-related gene cassettes between species and with the environment. As a result, alternatives to antibiotic treatments are desperately needed. In that vein, many treatments have been proposed and studied extensively in the fish-farming industry, including treatments that target Aeromonas quorum sensing. In this review, we discuss current strategies targeting quorum sensing inhibition and propose that such studies empower the development of novel chemotherapeutic approaches to combat drug-resistant Aeromonas spp. infections in humans.

Key points:

• Aeromonas notoriously acquires and maintains antimicrobial resistance, making treatment options limited.• Quorum sensing is an essential virulence mechanism in Aeromonas infections.• Inhibiting quorum sensing can be an effective strategy in combating Aeromonas infections in animals and humans.

2024-12-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Chiral superficially porous stationary phases for enantiomeric separation of condensed 1,4-dihydropyridine derivatives

Article

作者: Armstrong, Daniel W ; Burk, Ryan Jacob ; Salehi, Reza ; Gündüz, Miyase Gözde ; J, Siddharth Jaya Sajeevan ; Berthod, Alain ; Armstrong, Daniel W.

1,4-dihydropyridine (DHP) scaffold occupies a prominent position among all heterocyclic compounds owing to its versatile pharmacological properties, particularly its well-known calcium channel blocking activity. In the quest of developing new calcium channel blockers, fifty seven 5-oxo-hexahydroquinoline (HHQ) derivatives carrying DHP framework in a condensed ring system were recently synthesized as racemic mixtures. Due to their potential as drug candidates, enantiomers arising from the asymmetric center at the C-4 position of the HHQ ring were separated. Four modern columns packed with 2.7 µm superficially porous particles bonded with a chiral selector were used. The chiral selectors were three macrocyclic glycopeptide selectors: vancomycin, teicoplanin, and a macrocyclic derivative called nico. The fourth bonded selector was the dinitrobenzamido-tetrahydrophenanthrenyl derivative called Whelko. The four chromatographic modes were assayed with the mobile phase compositions: reversed phase with acetonitrile/buffer 30/70 %v/v, normal phase with hexane/ethanol 80/20 %v/v, and subcritical fluid chromatography with CO₂/methanol 80/20 %v/v at 25 °C. The WhelkoShell column was the most effective in separating this set of 57 compounds. Several enantioresolution factors passed 20 with enantioselectivity ratios higher than 4. Molecular modeling showed that the compounds had a T-shape that fitted well the molecular structure of the WhelkoShell selector in the normal or subcritical modes. Additionally, seven compounds had a second chiral center. The NicoShell column was able to separate all four stereoisomers of these compounds in the reversed phase mode. The preparative production of pure enantiomers of these compounds would be straightforward using the WhelkoShell column in the subcritical mode.

项与 The University of Texas at Arlington 相关的新闻（医药）

2024-10-23

·梅斯医学

轻轻一电，改善抑郁症？《自然-医学》：缓解率高出2倍之多

抑郁症是导致全球范围内残疾的主要原因之一，一线治疗策略是抗抑郁药联合心理治疗。临床上，超过1/3的抑郁症患者治疗后未能实现完全临床缓解。经颅直流电刺激（tDCS）是一种非侵入性脑刺激技术，通过置于头皮的两个或多个电极产生微弱直流电，来调节大脑皮质兴奋性。 ▲tDCS系统示意图（图片来源：参考文献[2]）既往研究发现，便携式的tDCS安全且耐受性良好，是抑郁症的潜在新一线治疗方案。但通常tDCS治疗需要连续治疗几周，且多数研究均在研究所开展，需要参与者每天接受访视，这在一定程度上限制了其临床应用前景。此外，既往已开展的研究纳入患者人数较少，且研究时间普遍限制在6周，仍需有大规模研究来佐证tDCS疗效。为此，来自伦敦国王学院、东伦敦大学、得克萨斯大学休斯顿健康科学中心等机构的研究团队共同开展了一项大型、双盲、随机优效性试验，结果显示，基于远程监督模式的为期10周家庭tDCS治疗抑郁症，显示出较好的疗效、可接受性和安全性，可有效缓解至少中度抑郁患者的症状。该研究发表于《自然-医学》（Nature Medicine）。研究共同作者，来自得克萨斯大学休斯顿健康科学中心的Machado-Vieira教授表示：“这项研究证实了基于家庭的tDCS在治疗抑郁症方面的安全性和积极有效性，有望帮助更多患者及时获得治疗”。截图来源：Nature Medicine 研究纳入174例抑郁症患者，其中69%为女性，至少为中度抑郁。所有患者既往未接受治疗、稳定服用抗抑郁药或接受心理治疗至少6周。基线时，汉密尔顿抑郁量表-17项（HDRS-17）评分（分数越高、病情越严重）平均分为19.07分。研究人员将患者随机纳入主动tDCS刺激组（87例）和假性tDCS刺激组（87例）。两组患者分别接受持续30分钟的2 mA直流电刺激，以及使用相同器械和应用程序进行假性刺激，假性tDCS刺激患者同样可感受到主动刺激的刺痛感，以充分模拟主动刺激。所有患者先接受为期10周的家庭环境tDCS治疗抑郁症，即每周5次，持续治疗3周，接着转为每周3次，持续治疗7周。10周家庭环境治疗结束后，进行为期10周的开放标签治疗，主动tDCS刺激组患者可继续接受每周3次的主动tDCS治疗，假性tDCS刺激组患者先接受每周5次，持续3周的主动tDCS刺激，再转为每周3次，治疗7周。整个研究过程中，研究人员均可进行远程监控，并根据机器传回的数据来判断患者操作的合规性。研究结果显示，基线至治疗第10周时，相比于假性tDCS刺激组，主动tDCS刺激组患者HDRS-17评分降低更多（9.41分 vs. 7.14分，P=0.012）。 ▲主动tDCS刺激组（蓝色圆点）和假性tDCS刺激组（黄色三角）的抑郁严重程度评分随时间的变化（图片来源：参考文献[1]）基于HDRS评分可知，主动tDCS刺激组患者临床应答率显著高于假性tDCS刺激组（58.3% vs. 37.8%，P=0.017）。主动tDCS刺激组患者缓解率高出假性tDCS刺激组2倍之多（44.9% vs. 21.8%，P=0.004）。此外，探索性分析还发现，两组患者的焦虑、轻躁狂症状均有所改善，且相比于假性tDCS刺激组，主动tDCS刺激组改善更明显。总之，这项研究表明基于家庭的tDCS可能是抑郁症的潜在一项治疗策略，其疗效高、患者可接受性强且安全性可靠。参考资料 [1] Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-03305-y [2] 唐睿, 宋洪文, 孔卓, 等. 经颅直流电刺激治疗常见神经精神疾病的临床应用专家共识[J]. 中华精神科杂志, 2022, 55(5): 327-382. DOI: 10.3760/cma.j.cn113661-20220527-00131 撰文 | 医学新视点编辑 | 阿拉斯加宝 ●大无语！夜班收了3个患者，欠费逃单跑了俩，共欠1万多！当事医生后续会被扣钱、写情况报告！公立医院不再收押金，如何保证就医诚信？ ●震撼！坐车9小时去大三甲看病，医生下班了，睡在座椅下，副主任医师心疼加号！医生：不想被道德绑架，渴望有加号、退号和拒绝就诊的权力 ●荒唐！医学生发布大体老师头骨合影至短视频平台，自称“无所畏惧”！网友怒批：轻佻无知、毫无尊重，这样搞我们以后谁还敢去捐献遗体？版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床结果

2024-09-26

·GlobeNewswire-Health Care

BioNTX Announces 2024 Tech Transfer Showcase Finalists Pitch Competition at the 2024 iC³ Life Science & Healthcare Innovation Summit

ARLINGTON, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- BioNTX is pleased to announce the finalists for the 3rd Annual Tech Transfer Showcase, set for Friday, October 4th, at the 2024 iC³ Life Science & Healthcare Innovation Summit. The Tech Transfer Showcase shines the spotlight on life science innovation that may be sitting on the shelf and strengthens the development of future leaders and entrepreneurs. This program is designed to assist academic institutions in presenting technologies available for licensing, collaboration and acquisition. The goal of the Tech Transfer Showcase is to connect Texas based academic institutions with Texas-based investors and industry executives that can help provide valuable insight into commercial readiness, market fit, business models, strategic partnerships, and commercial viability of all technologies. The 2024 competition was open to all Texas Universities. After submission, a panel of experienced judges reviews each university’s featured technology and selects the top six finalists to advance to the pitch showcase at the BioNTX annual Summit. In 2024, BioNTX has seen a 50% increase in applicants for this opportunity. A panel of knowledgeable judges have selected the top six finalists to advance to the pitch event at the iC³ Summit. The 2024 Tech Transfer Showcase finalists are: Baylor UniversityRice UniversityTexas Tech UniversityThe University of Texas at AustinThe University of Texas at DallasThe University of Texas Medical Branch “BioNTX is proud to provide a platform for university faculty and inventors to test their technology and receive expert guidance for the commercialization of their innovation,” reports Kathleen Otto, CEO, BioNTX. Each finalist will collaborate with a Tech Transfer judge to refine their pitch and will present their technology at the iC³ Life Science & Healthcare Innovation Summit for a chance to win a cash prize. “The BioNTX Tech Transfer Showcase is a perfect opportunity to get a glimpse into early-stage technologies coming out of the top universities in Texas. As a mentor and judge, it is very rewarding to see the progression and growth of the presenter and their pitches throughout the process,” said Chad Ronholdt, Co-founder, CEO of ASC Biosciences and Managing Director of NVB Ventures. Paul J. Corson, Chief Innovation and Entrepreneurship Officer for the University of Texas at Arlington, is the moderator of the Tech Transfer Office Showcase and Pitch Competition at the iC³ Life Science & Healthcare Innovation Summit on Friday, October 4, from 10 a.m. to 11 a.m. Corson states, “North Texas is a great place for life science startups, as evidenced by the amazing work I see at UT Arlington every day.” The Tech Transfer winner will be announced after the showcase and pitch competition at the Summit. To register for the 2024 iC³ Life Science & Healthcare Innovation Summit, please click here. About the 2024 iC3 Life Science SummitThe 10th Annual BioNTX iC³ Life Science & Healthcare Innovation Summit brings together the community and North Texas bioscience and healthcare innovation leaders for a two-day event from Thursday, October 3rd – Friday, October 4th. The iC³ Summit fosters collaboration between thought leaders, knowledge exchange, and explores the latest innovation, products, and services in the life sciences. We invite you to register for the 2024 iC³ Life Science & Healthcare Innovation Summit, please click here. About BioNTXBioNTX is the bioscience and healthcare innovation trade organization serving North Texas. The organization fosters innovation and community through collaborative networking events, high-level educational programming, professional development, market visibility, a purchasing consortium, and by being the voice for the North Texas biosciences and healthcare innovation community. Media Contact: Allison ChaneyCulver Public Relationsallison@culverpr.com

2024-06-18

·Science Daily

Mirror-image chemicals may revolutionize drug delivery

More than 130 years after cyclodextrins were first discovered and reported, a team of scientists has created chemical mirror images of these complex carbohydrates in the laboratory. This discovery may revolutionize how medications are delivered to patients. Cyclodextrins (CDs) are complicated carbohydrates, a term that describes the natural, sugar-based, starchy material that makes up much of fruits, vegetables and grains. Their unique chemical properties make them ideal for all sorts of uses, including air fresheners, medications and cosmetics. Scientists also are exploring their potential to treat cardiovascular diseases caused by atherosclerotic plaques. Now, more than 130 years after CDs were first discovered and reported, a University of Texas at Arlington team of scientists has created chemical mirror images of these complex carbohydrates in the laboratory. This discovery may revolutionize how medications are delivered to patients. Daniel W. Armstrong, the Robert A. Welch Distinguished University Chair in Chemistry, has co-authored a new peer-reviewed publication in Nature Synthesis describing mirror-image cyclodextrins for the first time along with his former graduate student Saba Aslani. "This discovery is exciting, as it may make it easier to formulate and deliver complex medications to patients," Armstrong said. "This missing piece of the puzzle definitely paves the way for additional gains in treating and curing disease." Other authors on the paper are from Northwestern University; University of Hong Kong; University of Wyoming; ZJU-Hangzhou Global Scientific and Technological Innovation Center in China; National University of Singapore; Universite d'Angers in France; Zhejiang University in China; and University of New South Wales in Australia. After creating these mirror-image CDs in the lab, researchers were able to confirm their discovery using X-ray crystallography and binding studies of other mirror-image molecules. "In the pharmaceutical industry, it is common and even mandated to synthesize and test such mirror-image drug entities, as they may have different medicinal properties and toxicities," Armstrong said. "Based on how popular CDs are already for delivering medications, this newly discovered mirror image may have even more biomedical uses. Plus, we know that such mirror-images carbohydrates are more resistant to biological degradation than their natural counterparts."

100 项与 The University of Texas at Arlington 相关的药物交易

登录后查看更多信息

100 项与 The University of Texas at Arlington 相关的转化医学

登录后查看更多信息